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meric proteins including phosphorylation and O’GlcNacylation. Finally we
explored the acute ex vivo effect of the modulation of O’GlcNac on the myo-
filament sensitivity to calcium. There was a significant contractile dysfunction
in obese subjects compared to normal subjects, in both the force (p=0.01) and
myofilaments sensitivity to calcium concerning the Fmax (p=0.03). No change
in the expression of genes encoding sarcomeric proteins or enzymes involved
in post-translationnal modification; nor phosphorylation modification of sarco-
meric proteins like cMLC2 or cTnI in obese patients was observed. Con-
versely, we showed in obese patients a decreasing O’GlcNacylation of
proteins of 25 kDa (p=0.007) and 130 kDa (p=0.03) which include the sarco-
meric proteins MLC2 and Troponin I. Finally, we pointed out that alteration
of the O’GlcNac level by Azaserin decreased the cardiac myofilaments sensi-
tivity to calcium pCa50 (p=0.05). This study highlights before clinical and
echocardiographic onset, an association between impaired contractile function,
an altered sensitivity to calcium, and a decreased O’GlcNacylation of possible
sarcomeric proteins in humans.
Abstract 0048 – Figure: Level of O’GlcNac of myofilaments proteins
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Neutrophil Gelatinase Associated Lipocalin or Lipocalin 2 (LCN2) is a
circulating protein, member of the lipocalin family, which binds MMP9
and modulates its stability and activity. We have recently shown that
LCN2 is a primary target of aldosterone/mineralocorticoid receptor (MR)
in endothelial cells, vascular smooth muscle cells and cardiomyocytes. We
hypothesized that LCN2 could be a mediator of aldosterone/MR profibro-
tic and proinflammatory effects in the cardiovascular system. Wild type
(WT) and LCN2 Knock Out (KO) mice were subjected to an uni-nephrec-
tomy aldosterone salt challenge (NAS, 200μg/kg/day of aldo, 1% NaCl in
tap water) for 4 weeks. Blood pressure (SBP) was measured by tail cuff
method. Cardiovascular fibrosis and inflammation were analyzed by RT-
PCR, western blot, immunohistochemistry and ELISA. There was no dif-
ference in SBP between transgenic mice compared to WT mice in basal
condition. With NAS challenge, SBP was increased only in WT mice
(SBP; CT 107±3, CT NAS 133±5, KO 109±3, KO NAS 115±3 mmHg).
Quantification of pro collagen I N-terminal peptide (PINP) in plasma
showed an increase of PINP due to NAS treatment in WT that was pre-
vented by LCN2 inactivation (CT 83±15, CT NAS 129±10, KO 70±19,
KO NAS 59±12 μg/l). In myocardium, NAS treatment increased collagen
type I and perivascular fibrosis in WT whereas KO were resistant to fibro-
sis (Collagen Volume Fraction; CT 19±3, CT NAS 28±2, KO 20±3, KO
NAS 20±3%). In aorta, collagen type I, vascular fibrosis and osteopontin
were also increased by NAS in WT. These increases were prevented by
LCN2 inactivation (CVF; CT 24±4, CT NAS 34±5, KO 21±2, KO NAS
28±2%). Our results show that LCN2 plays a key role in aldosterone/MR-
mediated vascular fibrosis and inflammation, but not in cardiac interstitial
fibrosis and vascular dysfunction. We are now analyzing 1) the specificity
of aldo/MR versus other pro-fibrotic challenges (AngII, catecholamines)
as well as 2) the role of inflammation in the effects mediated by Lcn2.
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Sympathetic overactivity is a hallmark of metabolic syndrome (MS). Data
showing sympathetic overactivity in patients with early cardiovascular and
metabolic disorders, i.e., prodromal forms of MS, are lacking. Sympathetic
activity was measured by microneurography (MSNA), heart rate variability
(HRV), blood pressure variability (BPV) and plasma and urinary catechol-
amines. β2-adrenergic receptor (β2-AR) and the G-protein coupled receptor
kinase 2 (GRK2) mRNA expression levels were tested as possible markers of
sympathetic activity in blood mononuclear cells (PBMCs). 40 healthy volun-
teers and 16 patients with established (  3 components of the MS) and 23
incomplete (two components) MS were compared. MSNA was not only
increased in patients with overt MS but also among patients with incomplete
MS (P<0.001). In PBMCs of patients with incomplete MS, a significant 3.4
fold increase in the β2-AR over GRK2 mRNAs expression ratio was observed
(P=0.001); this ratio correlated well with MSNA. (Funded by the Clinical
Research program of the French Ministery of Health)
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Admission glycaemia: the crystal ball to assess prognosis value after
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Introduction: High glycaemia at admission in STEMI patients is common
and associated with an increased risk of in-hospital and post-discharge death.
Aim: To evaluate the impact of admission glycaemia in the short prognosis
of diabetic and non-diabetic patients admitted for STEMI and to identify inde-
pendent predictors of post-ACS mortality.
Population and methods: This study included 567 patients admitted to a
single coronary care unit for STEMI, between January 2004 and June 2012.
Our population was divided in three groups according to the tertiles of gly-
caemia at admission (T1<7; T2=7-11 e T3>11 mmol/l). Rates of success after
revascularisation, intrahospital mortality, and ventricular arrhythmias were
collected
Results: Hyperglycaemia at admission was associated to worse cardiovas-
cular risk profile, more severe coronary disease (more 3 vessel disease),
incomplete revascularization, higher creatinine levels and more life threat-
ening ventricular arrhythmias (VT/VF). In the predefined tertiles, in-hospital
mortality was 4%, 5.2% and 14% (p<0.001). Life threatening arrhythmias
were respectively 2.4%; 4% and 9% (p:0.017). In the group of patients with
glycemia >11 mmol/l (224 patients), outcomes were similar between the dia-
betic and non diabetic patients with death rates respectively 13.8% and 13.9%
(p:0.988) In a multivariate analysis, predictive factors of intrahospital mor-
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